home / stock / adilw / adilw news

ADILW News and Press, Adial Pharmaceuticals Inc Warrant From 01/09/20

Stock Information
Company Name: Adial Pharmaceuticals Inc Warrant
Stock Symbol: ADILW
Market: NASDAQ
Website: adialpharma.com
Menu
ADILW ADILW Quote ADILW Short ADILW News ADILW Articles ADILW Message Board
Get ADILW Alerts

News, Short Squeeze, Breakout and More Instantly...
ADILW - Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received favorable opinions from the Finnish Medicines Agency ...
ADILW - Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a patent ...

ADILW - Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial

Reports regulatory progress in Europe and imminent commencement of clinical trial CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for a...

ADILW - Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites

CHARLOTTESVILLE, VA / ACCESSWIRE / October 29, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed the final packaging of its lead in...
ADILW - Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker

CHARLOTTESVILLE, VA / ACCESSWIRE / October 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a p...

ADILW - Adial Files Clinical Trial Application to Commence Phase 3 Trial

CHARLOTTESVILLE, VA / ACCESSWIRE / October 1, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted its Clinical Trial Application (CTA) to comme...

ADILW - Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its clinical activities. The Company reported that it is on...
ADILW - Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its previously manufactured supply of clinical trial mater...

ADILW - Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare

CHARLOTTESVILLE, VA / ACCESSWIRE / June 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ; ADILW ) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its Chief Medical Officer, Bankole Johnson, M.D., D.Sc., M.B., ChB...

ADILW - Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder

CHARLOTTESVILLE, VA / ACCESSWIRE / June 13, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the further strengthening of its intellectual property (IP) portfolio, as i...
Previous 10 Next 10